Denali Therapeutics Inc.
NASDAQ:DNLIBiotechnology
+$0.09 today
- Market cap
- $2.95B
- Beta
- 1.01
- P/E (TTM)
- -8.7
- EPS (TTM)
- -$2.72
Volume 2.37M
Average 1.84M
DNLI Long-term Investments
Investments the company intends to hold for more than a year.
Denali Therapeutics Inc.NASDAQ: DNLI
Long-term Investments · Q2 FY2026 · quarter ended Jun 2026
Long-term investments rises 192.5% from a year ago
Long-term investments stood at $229.53M at the end of Q2 FY2026, up 192.5% from a year earlier and up 243.2% from the prior quarter. Over 3 fiscal years it compounded at +303.2% a year.
Context
- Long-term investments amounted to 19.8% of total assets at the end of Q2 FY2026, up 13.1 pp from a year earlier.
- Long-term investments increased in 1 of the last 3 fiscal years.
What to watch
Whether long-term investments keeps rising in the next quarterly balance sheet after a +192.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 98.32M USD
- Year-over-year change
- -72.6%
- 4-year CAGR
- -30.7%
| Period | Period end | Long-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 98.32M | -72.6% |
| FY2024 | 2024-12-31 | 359.37M | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 1.5M | -99.6% |
| FY2021 | 2021-12-31 | 425.45M | — |
Long-term Investments vs competitors
How DNLI compares with its peers on the latest reported figures
- DNLI's Jun 2026 long-term investments of $229.53M is the 2nd highest of the 11 companies compared; the peer median is $0.
- Its year-over-year change of +192.5% is the 2nd highest of 5, against a peer median of -76.8%.
- Long-term investments amounts to 19.8% of total assets for DNLI, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $540.7M | +343.2% | — | 41.2% | |
| Jun 2026 | $229.53M | +192.5% | +303.2% | 19.8% | |
| Sep 2026 | $95M | -91.5% | +43.4% | 1.7% | |
| Sep 2026 | $19.82M | -62.0% | +8.9% | 0.7% | |
| Sep 2026 | $0 | -100.0% | — | 0.0% | |
| Jun 2026 | $0 | — | — | 0.0% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding DNLI) | $0 | -76.8% | +26.2% | 0.0% | |
Competitors are the stored peer set for DNLI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 293.48M | 218.04M | 127.11M | 174.96M | 205.33M |
| Short-term Investments | 571.93M | 1.12B | 907.41M | 657.37M | 662.55M |
| Net Receivables | 1.23M | 9.28M | 3.42M | 2.17M | 2.18M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 30.6M |
| Total Current Assets | 897.23M | 1.37B | 1.06B | 864.44M | 900.66M |
| Property, Plant & Equipment (Net) | 69.61M | 74.52M | 71.64M | 125.63M | 119.94M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 425.45M | 1.5M | 0 | 359.37M | 98.32M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 11.87M | 11.9M | 18.14M | 24.74M | 25.94M |
| Total Non-current Assets | 506.93M | 87.92M | 89.78M | 509.74M | 244.2M |
| Total Assets | 1.4B | 1.46B | 1.15B | 1.37B | 1.14B |
| Account Payables | 4.78M | 2.79M | 9.48M | 11.14M | 3.33M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 320.3M | 290.05M | 0 | 0 | 0 |
| Other Current Liabilities | 19.01M | 17.09M | 21.59M | 38.86M | 53.28M |
| Total Current Liabilities | 378.25M | 363.92M | 77.98M | 102.21M | 98.35M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 4.69M | 479K | 0 | 0 | 0 |
| Other Non-current Liabilities | 379K | 379K | 0 | 5.62M | 5.53M |
| Total Non-current Liabilities | 63.63M | 53.89M | 44.98M | 42.29M | 32.74M |
| Total Liabilities | 441.87M | 417.81M | 122.96M | 144.5M | 131.09M |
| Common Stock | 1.55M | 1.69M | 1.71M | 1.77M | 1.89M |
| Retained Earnings | (645M) | (970.99M) | (1.12B) | (1.54B) | (2.05B) |
| Accumulated OCI | (2.5M) | (6.89M) | 643K | 2.02M | 682K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 962.29M | 1.04B | 1.03B | 1.23B | 1.01B |
| Total Debt | 64.01M | 60.35M | 52.24M | 48.71M | 36.76M |
| Net Debt | (229.47M) | (157.69M) | (74.87M) | (126.25M) | (168.57M) |
Denali Therapeutics Inc.
NASDAQ:DNLI
Intrinsic Alpha fair value
Locked
Current Price
$18.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.